AG真人官方

SEC Form 4 filing: Director Jessica M. Bibliowicz reported the grant of 1,446 restricted stock units (RSUs) of Apollo Global Management, Inc. (APO) on 01 July 2025 under the company鈥檚 2019 Omnibus Equity Incentive Plan. Each RSU converts into one share of common stock when vested and, per Bibliowicz鈥檚 deferral election, shares will be issued after she leaves the Board.

Following the grant, the director鈥檚 total beneficial ownership rises to 14,472 shares, including 6,802 previously issued RSUs. The transaction carried a stated price of $0 because it is an equity award, not an open-market purchase.

• The RSUs vest in installments, subject to continued service.
• No derivative securities were bought or sold, and no cash changed hands.
• The filing does not disclose any sales, dispositions, or purchases by the insider beyond the single RSU grant.

The activity is routine board compensation and does not materially alter the company鈥檚 share count or governance profile, but it affirms alignment of director incentives with shareholder value.

Form 4 filing for KORU Medical Systems, Inc. (KRMD) discloses that director Shahriar Matin acquired 4,189 shares of common stock on 07/02/2025 at a reported price of $3.58 per share. Following the transaction, Matin鈥檚 direct ownership increased to 87,604 shares. No derivative security activity or additional explanatory notes beyond the standard boiler-plate language were provided. The filing was signed by Attorney-in-Fact Thomas Adams.

Ionis Pharmaceuticals (IONS) filed a Form 4 disclosing routine board compensation for non-employee director Allene M. Diaz on 07/01/2025. She received:

• 11,518 non-qualified stock options with a strike price of $39.94.
• 5,220 restricted stock units (RSUs).

Under the company鈥檚 Non-Employee Director Compensation Policy, total 2025 equity value was capped at $450,000 (ASC 718 grant-date fair value), so the awards were adjusted downward to stay within that limit.

Both the options and RSUs vest 100 % on the earlier of (i) the first anniversary of the grant or (ii) the next annual shareholder meeting. No shares are currently vested or exercisable.

After the grant, Diaz beneficially owns 11,518 derivative option securities and 9,299 RSUs, all held directly. No open-market purchases or sales occurred, and no cash changed hands; the filing reflects standard equity grants intended to align director incentives with shareholder interests.

On June 30 2025, Ovintiv Inc. (OVV) director Ralph Izzo received 40 Deferred Share Units (DSUs) as a dividend equivalent, recorded in a Form 4 filing. Each DSU economically equals one common share and will be held until the director retires from the Board. The transaction was priced at $0, reflecting a non-cash, routine accrual of board compensation. Following the allocation, Izzo鈥檚 total direct ownership increases to 5,125 DSUs. No derivative exercises, open-market purchases, or sales occurred, and there is no indication of any change in corporate strategy or insider sentiment beyond ordinary board compensation.

Novanta Inc. (NASDAQ: NOVT) entered into a Fourth Amended & Restated Credit Agreement on 27 June 2025 that replaces its 2019 facility scheduled to mature in March 2027. The new agreement provides an aggregate senior secured credit capacity of approximately US$1.0 billion, broken down into:

• 鈧�65.31 million 5-year Euro-denominated term loan
• $75 million 5-year US-dollar term loan
• $850 million 5-year revolving credit facility

The maturity is extended to June 2030, and an uncommitted accordion feature can raise total commitments by an additional $350 million, subject to customary conditions. Interest is set at (i) Base Rate + 0鈥�0.75 ppt or (ii) SOFR/SONIA/EURIBOR + 1.00鈥�1.75 ppt, with pricing tied to the company鈥檚 consolidated leverage ratio. A commitment fee applies to unused revolver capacity.

Key financial covenants tested quarterly include: (1) maximum consolidated leverage ratio of 3.5脳 (step-up to 4.0脳 for four quarters following qualifying acquisitions >= $50 million) and (2) minimum fixed-charge coverage ratio of 1.25脳. The facilities are secured by senior liens on substantially all assets of Novanta and certain subsidiaries and contain customary negative covenants on mergers, asset sales, indebtedness, investments and liens.

Required quarterly principal amortization begins September 2025 for the Euro term loan and September 2026 for the US term loan, with final balloon payments due at maturity. Prepayments from asset sales, casualty events or incremental debt are mandatory, while voluntary prepayments and commitment reductions are permitted without premium.

Outstanding borrowings under the prior facility were $392.4 million as of 28 March 2025. The new structure enhances liquidity headroom, extends tenor, and provides interest-rate optionality, but also secures the debt and maintains leverage limits that investors should monitor.